Liquid reservoir transdermal patch for the administration of ketorolac
AssigneePharmetrix Corporation
InventorsJudy M. Mohr, Richard W. Baker, Lisa A. Nakaji
Life of this patent
Estimating the term…
Abstract
The invention is directed to a patch for the transdermal delivery of the racemic form or the active enantiomer of the analgesic ketorolac. The transdermal patch is capable of delivering therapeutically effective doses of the drug for a period of 12 hours or more. The patch is capable of delivering the racemate of ketorolac at a flux rate of 40 .mu.g/cm.sup.2 .multidot.hr or more, and of the active enantiomer at a flux rate of 20 .mu.g/cm.sup.2 .multidot.hr or more.
Claims16
A patch for the transdermal administration of ketorolac through a patient's skin for a period of 12 hours or more, said patch comprising:
- (a) an occlusive backing layer having a skin-facing side and a peripheral edge,
- (b) a porous membrane having a skin-facing side and a peripheral edge sealed to said peripheral edge of said backing layer and defining a drug depot therebetween, and
- (c) said drug depot comprising:
- i. ketorolac, and
- ii. an enhancer combination in which said ketorolac is dispersed, said enhancer combination comprising a first portion of a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol, and
- (d) an adhesive layer comprising an adhesive and a second portion of said plasticizing-type enhancer, said adhesive layer being in contact with said skin-facing side of said porous membrane,
- wherein said patch delivers ketorolac through the skin facing side of said patch and through said patient's skin at a flux rate of about 40 .mu.g/cm.sup.2 .multidot.hr or more.
A patch for the transdermal administration of (-) ketorolac through a patient's skin for a period of 12 hours or more, said patch comprising:
- (a) an occlusive backing layer having a skin-facing side and a peripheral edge,
- (b) a porous membrane having a skin-facing side and a peripheral edge sealed to said peripheral edge of said backing layer and defining a drug depot therebetween, and,
- (c) said drug depot comprising:
- i. ketorolac, and
- ii. an enhancer combination in which said ketorolac is dispersed, said enhancer combination comprising a first portion of a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol, and
- (d) an adhesive layer comprising an adhesive and a second portion of said plasticizing-type enhancer, said adhesive layer being in contact with said skin-facing side of said porous membrane,
- wherein said patch delivers (-) ketorolac through the skin facing side of said patch and through said patient's skin at a flux rate of about 20 .mu.g/cm.sup.2 .multidot.hr or more.
A method of administering ketorolac to a patient in need of such administration, comprising:
- (a) applying to the skin of said patient a transdermal patch having a skin-facing side, said patch comprising:
- i. an occlusive backing layer having a skin-facing side, and
- ii. means defining a drug depot having a skin-distal side in contact with said skin-facing side of said backing layer, said drug depot containing ketorolac and an enhancer combination comprising a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol, and
- (b) delivering ketorolac through the skin-facing side of said patch and through said patient's skin at a flux rate of about 40 .mu.g/cm.sup.2 .multidot.hr or more.
A method of administering ketorolac to a patient in need of such administration, comprising:
- (a) applying to the skin of said patient a transdermal patch having a skin-facing side, said patch comprising:
- i. an occlusive backing layer having a skin-facing side, and
- ii. means defining a drug depot having a skin-distal side in contact with said skin-facing side of said backing layer, said drug depot containing (-) ketorolac and an enhancer combination comprising a plasticizing-type enhancer and a solvent-type enhancer, said plasticizing-type enhancer being a member selected from the group consisting of isopropyl myristate, caprylic triglyceride, capric triglyceride and glyceryl oleate, and said solvent-type enhancer being a member selected from the group consisting of ethanol, propanol and propylene glycol, and
- (b) delivering (-) ketorolac through the skin facing side of said patch and through said patient's skin at a flux rate of about 20 .mu.g/cm.sup.2 .multidot.hr or more.
Dependencies are inferred from the claim text.